China’s Mabworks Biotech Raises US$160M in Two Series C Rounds

China’s Mabworks Biotech Raises US$160M in Two Series C Rounds

The company develops therapeutic antibodies via integrated technology.

Beijing-based biotech and pharmaceutical company Beijing Mabworks Biotech announced that it had raising funding up to RMB 1.13 billion (US $160 million) in its Series C1 and C2, DealStreetAsia reported today.

The capital will be used to strengthen Mabworks’ research and development efforts, and commercialize its macromolecule drugs.

The round was led by CICC Qide Innovative Biopharmaceutical Equity Investment Fund, CITIC Securities, healthcare-focused fund Lyzz Capital, and Huge Capital, the report said.

CICC Capital, the investment arm of state-owned Chinese investment bank China International Corporation Limited, acted as an advisor to the deal.

Among others, Bank of Communications’ subsidiary BOCOM International, Beijing E-Town International Investment & Development, SDIC Unity Capital, Yuexiu Financial Holdings’ Industrial Fund, and Sealand Innovation participated in the round.

Other investors of the company include GTJA Investment Group, Medfine Capital, QS Capital, and Beijing Yizhuang Biomedical Fund, from whom Mabworks previously raised funds in 2016, according to the report.

“We will further expedite our capacity in the emerging market, to provide affordable drugs for Chinese patients suffering from cancers and autoimmune diseases. Also, we do expect we can be more competitive by navigating the advantages in macromolecules research and partnerships with institutions,” Mabworks’ Chairman and President Dr Feng Li said in the company’s statement.

Mabworks is a clinical stage biopharma company that develops antibody medication. It uses integrated technology platforms to develop, manufacture and commercialize therapeutic antibodies. The company says that it has over 50 patents in and out of China.

Mabworks has developed over 15 biomedical assets through clinical trials in China and the United States. Their solutions cover various critical illnesses such as lung cancer, breast cancer, colorectal cancer, leukaemia, and infectious diseases. Additionally, the biopharmaceutical venture has collaborated with oncology and autoimmune diseases drug maker InnoCare Pharma to develop a novel therapy for B-cell lymphoma, the report mentioned.

The company’s previous funding round was a Series B in January 2017, according to Crunchbase data. Mabworks raised RMB 270 million (about US$38 million) in the round.

Private equity firm GTJA Investment Group acted as the lead investor in the Series B which also saw participation from Shanghai-based investment firm MF Capital and Hong Kong-based Harvest Global Investment.

Crunchbase data also shows that MF Capital led the 2003-founded Mabworks’ Series A for RMB 100 million (about US $14 million) in 2016.

Header image by Bill Oxford on Unsplash

SHARE THIS STORY

Share on facebook
Share on twitter
Share on linkedin
Share on email

RELATED POSTS

Discover-the-Best-Thin-and-Light-Laptops-to-Suit-Your-Needs

Discover the Best Thin and Light Laptops to Suit Your Needs

In today’s fast-paced world, a laptop that seamlessly combines sleek design, impressive power and exceptional portability is no longer a luxury but a necessity. Whether you’re a student, a professional or someone with a creative passion, finding the perfect thin and light laptop is crucial for staying productive and mobile.

Top 5 Technologies That Will Make Mars Habitable

Top 5 Technologies That Will Make Mars Habitable

Mars, the fourth planet from the Sun, has long captivated the curiosity of scientists. Some of the most intelligent minds—Buzz Aldrin, Neil Degras Tyson and Stephen Hawking—agree that humankind should work towards occupying Mars. And there is a good reason for that. When life on Earth was evolving, Mars was going through significant climate change.

Exploring the Best Robo-Advisors for Smart Investors

Investing Made Easy: Exploring the Best Robo-Advisors for Smart Investors

Are you ready to revolutionize your investment approach and maximize your profits? Consider robo-advisors—the AI-powered automated investment advisor that uses algorithms to provide financial advice and manage investments. They are typically much cheaper than traditional advisors, and they can be a good option for investors—even beginners—who are looking for an automated and efficient way to manage their portfolios.

Is Generative AI Threatening Creativity

ChatGPT and Dall-E: Is Generative AI Threatening Creativity?

Much has been written about the rise of ChatGPT, DALL-E and other such generative artificial intelligence (AI) tools. Some worry they will steal jobs, while other professionals laud the tools for making their jobs easier. In support of the latter, AI is anticipated to take on repetitive and mundane tasks, freeing up time to be more creative and human.

Top Generative AI Startups to Watch in 2023

Top Generative AI Startups to Watch in 2023

Artificial intelligence (AI) is constantly evolving and among its latest breakthroughs is the promising technology of generative AI. This innovative technology refers to a category of AI algorithms that create new outputs based on their training data. Unlike traditional AI systems, generative AI generates content like images, text and audio instead of focusing on pattern recognition and predictions.